1. "Michael Morris"
  2. "Susan Slovin"
  3. "Journal of Clinical Oncology"
Formats
  1. Meeting Abstract (37)
  2. Journal Article (5)
Groups
  1. Department of Medicine (42)
  2. Genitourinary Oncology Service (42)
  3. Hematologic Malignancies, Division of (42)
  4. Solid Tumor Oncology Division (42)
  5. GSK Faculty (26)
  6. Radiology, Department of (18)

More Groups

People
  1. Michael Morris (42)
  2. Susan Slovin (42)
  3. Howard Scher (39)
  4. Dana Rathkopf (31)
  5. Daniel Danila (21)
  6. Steven Larson (15)

More People

Years
  1. 2022 (1)
  2. 2020 (1)
  3. 2019 (5)
  4. 2018 (1)
  5. 2017 (2)
  6. 2016 (5)

More Years

Publications
  1. Journal of Clinical Oncology (42)
Publishers
  1. American Society of Clinical Oncology (42)

Results (42)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality
    Meeting Abstract

    Keegan, N. M.; Vasselman, S. E.; Barnett, E.; Nweji, B.; Carbone, E.; Blum, A.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes
    Meeting Abstract

    Mota, J. M.; Barnett, E.; Nauseef, J.; Stopsack, K. H.; Wibmer, A. G.; Danila, D. C.; Rathkopf, D. E.; Slovin, S. F.; Kantoff, P. W.; Scher, H. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)
    Meeting Abstract

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Baser, R.; Stein, M. N.; Shevrin, D. H.; Vaishampayan, U. N.; Mayer, T. M.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations
    Meeting Abstract

    Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)
    Meeting Abstract

    McKay, R. R.; Werner, L.; Jones, A.; Choudhury, A. D.; Pomerantz, M.; Sweeney, C.; Bubley, G. J.; Slovin, S. F.; Morris, M. J.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save